GASTRIC CANCER

This study tests a drug called zolbetuximab for people with advanced stomach or gastroesophageal junction cancer that has a specific protein (CLDN18.2). The drug attaches to this protein and helps the immune system attack the tumor. Participants receive zolbetuximab alone or comb…

This early-phase study tests a personalized cell therapy for people with certain advanced cancers (bladder, melanoma, head/neck, ovarian, lung, esophageal, stomach, sarcoma) that carry a protein called MAGE-A4. Patients' own immune cells are genetically modified to recognize and …

This study tests a new device called the Luso-Cor esophageal stent for closing leaks (fistulas) that can happen after weight-loss surgery or cancer surgery on the stomach or esophagus. About 180 adults who develop such leaks will be randomly assigned to get either the new stent, …

This early-stage study tests an experimental drug called BL-M17D1 in 120 adults with advanced solid tumors that have a specific protein (HER2) or a HER2 gene change. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. Participants mus…

This study tests whether adding an immunotherapy drug (atezolizumab) to standard chemotherapy and targeted therapy (trastuzumab) can improve outcomes for people with HER2-positive stomach or gastroesophageal junction cancer that can be surgically removed. About 42 participants wi…

This study tests a new drug combination (RC48-ADC plus toripalimab and either chemotherapy or trastuzumab) as a first treatment for advanced stomach cancer that has spread. About 201 adults with or without a specific protein (HER2) will participate. The goal is to see if the comb…

This study tests a new drug called Q702 combined with pembrolizumab (a standard immunotherapy) in people with advanced esophageal, stomach, liver, or cervical cancer that has worsened after prior treatment. The goal is to see if the combination is safe and can shrink tumors or sl…

This early-phase study tests several new drug combinations in people with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the drugs can shrink tumors. About 352 adults with specific cancer types will participate…

This early-phase trial is testing whether giving immunotherapy drugs (nivolumab alone or with relatlimab) before standard chemoradiation is safe and feasible for people with operable stage II/III esophageal or gastroesophageal junction cancer. The study involves 32 participants a…

This study tests a combination of two drugs (vorbipiprant and balstilimab) in people with advanced colorectal or other gastrointestinal cancers that have not responded to prior treatments. The goal is to see if the combination is safe and can shrink tumors or stop them from growi…

This study tests an experimental drug called AZD5305, a PARP inhibitor, in people with advanced solid tumors (e.g., ovarian, breast, prostate, lung cancer). The goal is to see if the drug is safe and can shrink tumors when given alone or with other anti-cancer medicines. About 70…

This study tests a new drug called MCLA-129 in people with advanced lung, stomach, esophageal, head/neck, or colorectal cancers that have not responded to standard treatments. The drug is a bispecific antibody designed to attack two cancer-related targets at once. The goal is to …

This study tests a treatment for stomach cancer that has spread to the lining of the abdomen (peritoneal carcinomatosis). About 40 adults who have already had at least 3 months of standard chemotherapy will receive a combination of intravenous (IV) and intraperitoneal (IP) chemot…

This study is for people with advanced solid tumors (like lung, bladder, or skin cancer) whose disease has progressed after standard immunotherapy. It tests a new drug combination designed to boost the immune system to fight cancer. About 40 participants will receive the experime…

This study tests a new treatment approach for people with advanced stomach or gastroesophageal junction cancer that has spread. Participants first receive targeted radiation and a drug called olaparib, followed by a combination of olaparib and pembrolizumab. The goal is to see if…

This study tests an experimental drug called INBRX-106, given alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced solid tumors (like lung, head and neck, melanoma, stomach, kidney, or bladder cancer) that have stopped responding to standard treatment…

This early-phase trial tests a new drug called TST001, an antibody that targets a protein (CLDN18.2) found on some cancer cells. It is being studied alone or with other treatments in about 150 people with advanced stomach, esophageal, or pancreatic cancers that have not responded…

This study compares 4 months versus 6 months of chemotherapy (capecitabine and oxaliplatin) in 1024 stomach cancer patients who had surgery. The goal is to see if the shorter treatment is just as effective at preventing cancer from coming back, while causing fewer side effects. P…

This study tests a new drug called AZD0901 in 33 adults with advanced stomach or gastroesophageal junction cancer that has spread or cannot be removed. Participants must have a specific protein (CLDN18.2) on their cancer cells and have already tried at least one prior treatment. …

This early-phase study tests the safety of a new drug called AB598, given alone or with other treatments, in about 40 people with advanced solid tumors (e.g., lung, bladder, breast, or ovarian cancer). The main goal is to see if the drug is safe and tolerable. Participants must h…

This early-phase study is testing whether a diet low in leucine (a building block of protein) is safe for people with stomach cancer who are waiting for surgery. About 37 participants will follow the special liquid diet, and researchers will measure changes in blood amino acids, …

This study is testing a new drug called bemarituzumab combined with other cancer treatments for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if the combination is safe and helps shrink tumors. About 72 adul…

This study tests whether adding the drug bemarituzumab to standard chemotherapy and immunotherapy (nivolumab) helps people with advanced stomach or gastroesophageal junction cancer live longer. The trial includes about 515 adults whose tumors have a specific protein called FGFR2b…

This study tests an experimental drug called HFB200603, alone or with another immunotherapy (tislelizumab), in adults with advanced solid tumors like kidney, lung, skin, stomach, or colorectal cancer. The goal is to find a safe dose and see how well the body tolerates it. About 8…

This early-stage study tests a new drug (RO7496353) combined with an immunotherapy drug, with or without chemotherapy, in people with advanced lung, stomach, pancreatic, or bladder cancers. The main goal is to check safety and how well the body tolerates the treatment. About 102 …

This study tests a new drug, ASKB589, combined with chemotherapy (CAPOX) and an immunotherapy (PD-1 inhibitor) in 62 people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if the combination is safe and helps control…

This early-phase trial tests a new treatment called LB1908, which uses a patient's own immune cells (T-cells) engineered to recognize and attack cancer cells that have a protein called claudin 18.2 on their surface. The study includes adults with advanced stomach, gastroesophagea…

This study tests a new drug called IDX-1197 combined with standard chemotherapy (XELOX or irinotecan) in people with advanced stomach cancer that has spread. The goal is to find the safest dose and see if the combination helps control the cancer. About 87 adults who have not had …

This early-phase trial tests whether giving healthy donor NK cells along with two drugs (vactosertib and IL-2) is safe and helps the cells survive longer in people with advanced colorectal, stomach/esophageal, or blood cancers. About 12 participants will receive the combination t…

This study tests a combination of three drugs (fruquintinib, sintilimab, and SOX chemotherapy) in 42 people with advanced stomach cancer that has spread but might still be removable. The goal is to shrink the tumors enough to allow complete surgical removal. The main focus is on …

This study tests an experimental drug called AZD7789 in people with advanced lung, stomach, or gastroesophageal cancer that has spread. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals are to check safety and see if the drug…

This early-phase study tests an experimental cell therapy called P-MUC1C-ALLO1 in 180 adults with advanced solid tumors (e.g., breast, ovarian, lung, pancreatic cancers) that have not responded to standard treatments. The therapy uses donor immune cells engineered to attack cance…

This study tests a low dose of the immunotherapy drug nivolumab, alone or with chemotherapy, in people with advanced colorectal or stomach cancers that have a specific genetic feature (MSI/dMMR). The goal is to see if this approach can shrink tumors before surgery or control the …

This early-phase study tests a new drug, AI-061, which combines two immunotherapy agents (anti-PD-1 and anti-CTLA-4) into one treatment for people with advanced solid tumors that have stopped responding to standard therapies. The main goal is to find the safest dose and check for…

This study tests whether adding an experimental drug (ONO-4578) to standard chemotherapy and immunotherapy can help people with advanced stomach cancer live longer without their cancer growing. About 226 adults who have not had chemotherapy before will take part. The goal is to s…

This study tests if a less invasive surgery (using one or a few small cuts) is safe and effective for advanced stomach cancer. About 108 participants will undergo this procedure to see if it can remove enough lymph nodes and reduce complications. The goal is to improve recovery w…

This early-phase study tests an experimental drug called RNDO-564, alone or with pembrolizumab, in adults with advanced solid tumors (like bladder, lung, or breast cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the best dose,…

This early-stage study tests a new drug called TORL-2-307-ADC in 163 people with advanced solid tumors, including stomach, pancreas, and esophageal cancers. The main goals are to find a safe dose and check for side effects. Researchers will also see if the drug can shrink tumors …

This study tests an experimental drug called HFB200301, alone or with another drug (tislelizumab), in adults with advanced solid tumors like stomach, kidney, or lung cancer. The main goal is to find safe doses and check for side effects. About 72 people will take part, and the st…

This study tests a combination of three drugs (lenvatinib, pembrolizumab, and FLOT chemotherapy) given before and after surgery for stomach cancer. The goal is to see if this approach can shrink tumors significantly or make them disappear completely. The study involves 43 adults …

This study tests whether adding the drug bemarituzumab to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer. The trial includes about 547 adults whose tumors have high levels of a protein called FGFR2b. Participants receive e…

This study tests a new magnetic method to find cancer that has spread to nearby lymph nodes in people with stomach or esophagus cancer. About 60 adults who are scheduled for surgery to remove their cancer will receive a magnetic tracer injection before surgery. Doctors will then …

This study looks at whether a special type of CT scan (spectral CT) combined with a genetic marker (MSI) can more accurately predict if stomach cancer has spread to nearby lymph nodes. Researchers will compare the scan results to the actual findings from surgery in 260 adults wit…

This study screens 500 adults in South Florida for H. pylori, a stomach infection that can lead to chronic gastritis, ulcers, and even stomach cancer. Those who test positive receive free treatment right away. The goal is to catch and treat the infection early to prevent serious …

This study tests whether personalized screening—using stool tests, blood tests, and risk scores—can better prevent stomach and colon cancer in adults aged 50-75. Researchers will enroll 40,000 healthy participants and track them over time. The goal is to find the most effective w…

This study screens people in South Florida for H. pylori, a stomach infection that can lead to chronic inflammation, ulcers, and even stomach cancer. Those who test positive receive treatment, and the study compares at-home retesting versus standard retesting to confirm the infec…

This study tests whether using a FitBit and a mobile app can help people who have had surgery for stomach, liver, colon, or other GI cancers avoid going back to the hospital. About 107 adults who own a smartphone and are scheduled for surgery will either use the devices or get us…

This study tests a surgical technique that creates a pouch from the small intestine to replace the removed stomach. The goal is to reduce dumping syndrome—a common, unpleasant side effect—and improve nutrition and quality of life. About 26 adults with stomach cancer or a high-ris…

This study looks at two types of surgery for people with advanced stomach cancer that is causing a blockage. The goal is to see which surgery—removing part of the stomach or creating a bypass around the blockage—better relieves symptoms like nausea and vomiting. About 63 patients…

This study reviews medical records from 230 adults across 15 hospitals in 2 countries to understand how brain metastases from stomach and esophageal cancers are treated. The goal is to see which local treatments (like surgery or radiation) work best and how long patients live aft…

This study collects leftover tissue, blood, and other body fluids from 6,000 people with benign or malignant tumors of the soft tissue, gastrointestinal tract, or abdomen. Researchers will use these samples to learn more about what causes these cancers and how to better prevent, …